L A Carleton - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

L A Carleton

Showing results (1-10 of 4) with videos related to

Pageof 1

Sort By:

British Journal of Biomedical Science|October 17, 2003

Survey of microbial air sampling in the NHSW M Giddings, L A Carleton, J G Cunniffe

Communicable Disease and Public Health|April 25, 2000

Air sampling--why, where, and how to do it!W M Giddings, L A Carleton, J G Cunniffe

Cell Death & Disease|May 3, 2014

Nerve growth factor-mediated inhibition of apoptosis post-caspase activation is due to removal of active caspase-3 in a lysosome-dependent mannerK Mnich, L A Carleton, E T Kavanagh, et al.

British Journal of Cancer|September 21, 2013

The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistanceA P Toner, F McLaughlin, F J Giles, et al.

Pageof 1

Search research articles

Showing results (1-10 of 4) with videos related to

Sort By:

Pageof 1

British Journal of Biomedical Science|October 17, 2003

Survey of microbial air sampling in the NHSW M Giddings, L A Carleton, J G Cunniffe

Communicable Disease and Public Health|April 25, 2000

Air sampling--why, where, and how to do it!W M Giddings, L A Carleton, J G Cunniffe

Cell Death & Disease|May 3, 2014

Nerve growth factor-mediated inhibition of apoptosis post-caspase activation is due to removal of active caspase-3 in a lysosome-dependent mannerK Mnich, L A Carleton, E T Kavanagh, et al.

British Journal of Cancer|September 21, 2013

The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistanceA P Toner, F McLaughlin, F J Giles, et al.

Pageof 1